• Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies

  • Oct 22 2024
  • Length: 21 mins
  • Podcast

Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies

Listen for free

View show details

  • Summary

  • In this episode, Caitlin Costello, MD, discusses important topics related to relapsed/refractory (R/R) multiple myeloma (MM), including:

    • 3 bispecific antibodies approved for the treatment of R/R MM that target BCMA or GPRC5D
    • The role of bispecific antibodies in R/R MM
    • Safety considerations for patients while receiving a bispecific antibody
    • Emerging data and clinical trials with bispecific antibodies
    • Key clinical pearls for optimal use of bispecific antibodies


    Presenter:

    Caitlin Costello, MD
    Clinical Professor of Medicine
    Director, Multiple Myeloma Program
    Division of Blood and Marrow Transplantation
    Moores Cancer Center
    UC San Diego
    La Jolla, California

    Link to full program:
    https://bit.ly/40bjFCZ
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available